BAE Systems Helps Ireland Lead the Way With First Plug-In Electric Hybrid Propulsion Systems on Public Buses
10.12.2020 17:00:00 EET | Business Wire | Press release
BAE Systems, a world leader in electric propulsion, has delivered the first plug-in capable electric hybrid propulsion systems to Alexander Dennis Limited who are supplying new buses to Ireland. The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005589/en/
The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year. (Photo: Alexander Dennis Limited)
The Series-ER system builds on the company’s more than 20 years of innovation and proven technology and powers more than 13,000 buses around the world. That technology is on buses in service throughout Europe, including cities such as Brighton, London, Namur, and Paris. The Irish buses are the first in the world to benefit from the company’s new plug-in technology.
This means that as well as using the efficient onboard generator to charge itself while the bus is on the move, the buses can now also plug into the grid for power, giving operators another way to recharge their buses.
The Series-ER system enables buses to run for up to five kilometers (three miles) at a time with the engine turned off. This capability provides towns and cities with a new opportunity to improve air quality. The buses will use up to 35 percent less fuel when compared to a conventional bus.
“Clean transportation technology in our cities is critical to reach a zero emission future,” said Ian Wilson, director of business development for Power & Propulsion Solutions at BAE Systems. “Our system will help Ireland take the next step towards full electrification and improve the air quality where people live, work and visit.”
“The Alexander Dennis Enviro400ER is ideally suited for flexible operating needs including zero-emission running at air pollution hotspots,” said Paul Davies president and managing director at ADL. “With the ability to externally charge the batteries, the use of on-board power generation can be further reduced. This new generation of double deck buses for Ireland once again demonstrates that with ADL’s focus on innovation, we are building the buses our cities need to solve their transport challenges.”
The bus propulsion system includes a highly efficient electric motor and generator, an enhanced battery, and smart electronic controls to create a clean form of electric drive propulsion for the buses. It allows operators to take advantage of green grid power, and sets them up for full electric operation in the future. Operators can now use the grid for power – much like an all-electric bus – and add more battery capacity to increase their engine off time. In many instances this will mean an entire route can operate on grid power when the necessary charging infrastructure is in place.
BAE Systems develops and services its technology at its facilities in Endicott, New York, and Rochester, UK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005589/en/
Contact information
Anthony DeAngelis, BAE Systems
Mobile: +1 603-714-3664
anthony.deangelis@baesystems.com
www.baesystems.com/US
@BAESystemsInc
Sean Hills, BAE Systems
Mobile: +447827 991666
sean.hills3@baesystems.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
